A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors Article

Rocha-Lima, CM, Bayraktar, S, MacIntyre, J et al. (2012). A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors . CANCER, 118(17), 4262-4270. 10.1002/cncr.27428

cited authors

  • Rocha-Lima, CM; Bayraktar, S; MacIntyre, J; Raez, L; Flores, AM; Ferrell, A; Rubin, EH; Poplin, EA; Tan, AR; Lucarelli, A; Zojwalla, N



  • Background: E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids). Methods: In a phase 1 study, E7974 was given intravenously over a 2- to 5-minute infusion on day 1 of every 21-day cycle. Adult patients with advanced refractory solid tumors who had adequate organ function and Eastern Cooperative Oncology Group performance status 0 to 2 were eligible for this study. A modified Fibonacci schema was used. The maximal tolerated dose (MTD) was the dose where <2 of 6 patients developed a dose-limiting toxicity (DLT). Results: Twenty-eight patients (19 men and 9 women; median age, 64 years) treated at different cohort dose levels (0.18 mg/m 2, 0.27 mg/m 2, 0.36 mg/m 2, 0.45 mg/m 2, and 0.56 mg/m 2) received a total of 66 courses of E7974. The MTD was established at 0.45 mg/m 2, where 1 of 6 patients experienced DLT (grade 4 febrile neutropenia). Of the 17 refractory colon cancer patients with a median of 3 prior treatments, stable disease was seen in 7 patients (41%). There were no tumor responses. Median progression-free survival was 1.2 months, and median overall survival was 6.7 months. In pharmacokinetic analysis, E7974 was characterized by a fast and moderately large distribution (37.95-147.93 L), slow clearance (2.23-7.15 L/h), and moderate to slow elimination (time to half-life, 10.4-30.5 hours). Conclusions: This study shows that E7974 once every 21-day cycle shows antitumor activity in patients with refractory solid tumors. The recommended phase 2 dose is 0.45 mg/m 2. Cancer 2012. © 2011 American Cancer Society.

publication date

  • September 1, 2012

published in

Digital Object Identifier (DOI)

start page

  • 4262

end page

  • 4270


  • 118


  • 17